Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-06-21

AUTHORS

Maria I. Carlo, Martin H. Voss, Robert J. Motzer

ABSTRACT

Key PointsCheckpoint inhibitors have shown promising efficacy and manageable safety profiles for patients with advanced renal cell carcinoma (RCC)The programmed cell death protein 1 (PD-1) inhibitor nivolumab prolongs overall survival in patients with advanced RCC following therapy with an antiangiogenesis agent and has FDA approval in this settingPromising combinations of checkpoint inhibitors with other checkpoint inhibitors or targeted therapies are being compared with antiangiogenic agents for patients with advanced RCC in clinical trialsOther novel immune therapies such as vaccines, cytokine-induced killer cells, and T-cell agonists for advanced RCC are being studied in clinical trialsFurther studies should focus on how to best select patients who will benefit from immune therapies and on how to choose rational combination strategies More... »

PAGES

420-431

References to SciGraph publications

  • 2015-07-31. Combination cancer immunotherapy and new immunomodulatory targets in NATURE REVIEWS DRUG DISCOVERY
  • 2012-03-22. The blockade of immune checkpoints in cancer immunotherapy in NATURE REVIEWS CANCER
  • 2010-04-28. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2004-05. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity in NATURE REVIEWS IMMUNOLOGY
  • 2014-07-08. Therapeutic vaccines for cancer: an overview of clinical trials in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2012-07-29. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival in NATURE MEDICINE
  • 2010-11-11. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-01-27. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-12-23. Clinical blockade of PD1 and LAG3 — potential mechanisms of action in NATURE REVIEWS IMMUNOLOGY
  • 2014-04-10. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer in BMC CANCER
  • 2014-11-18. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2014-04-02. Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma in ARCHIVES OF PHARMACAL RESEARCH
  • 2011-12-21. Cancer immunotherapy comes of age in NATURE
  • 2012-03-22. Combining immunotherapy and targeted therapies in cancer treatment in NATURE REVIEWS CANCER
  • 2009-09-27. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal in NATURE IMMUNOLOGY
  • 2013-06-16. Mutational heterogeneity in cancer and the search for new cancer-associated genes in NATURE
  • 2009-03. Myeloid-derived suppressor cells as regulators of the immune system in NATURE REVIEWS IMMUNOLOGY
  • 1990-01. Immunohistological distribution of 5T4 antigen in normal and malignant tissues in BRITISH JOURNAL OF CANCER
  • 2008-02. The reverse stop-signal model for CTLA4 function in NATURE REVIEWS IMMUNOLOGY
  • 2015-04-21. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nrurol.2016.103

    DOI

    http://dx.doi.org/10.1038/nrurol.2016.103

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1053015375

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/27324121


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Renal Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Cycle Checkpoints", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carlo", 
            "givenName": "Maria I.", 
            "id": "sg:person.013003741441.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013003741441.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Voss", 
            "givenName": "Martin H.", 
            "id": "sg:person.0577111044.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Motzer", 
            "givenName": "Robert J.", 
            "id": "sg:person.01234500340.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nature10673", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044278169", 
              "https://doi.org/10.1038/nature10673"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd4591", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016866071", 
              "https://doi.org/10.1038/nrd4591"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature12213", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021761707", 
              "https://doi.org/10.1038/nature12213"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1990.20", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026132956", 
              "https://doi.org/10.1038/bjc.1990.20"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri2253", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029881358", 
              "https://doi.org/10.1038/nri2253"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri3790", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009414011", 
              "https://doi.org/10.1038/nri3790"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrclinonc.2014.111", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044950640", 
              "https://doi.org/10.1038/nrclinonc.2014.111"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.2883", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009869790", 
              "https://doi.org/10.1038/nm.2883"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-14-251", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039547181", 
              "https://doi.org/10.1186/1471-2407-14-251"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-8-42", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038769108", 
              "https://doi.org/10.1186/1479-5876-8-42"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.1790", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018507970", 
              "https://doi.org/10.1038/ni.1790"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12272-014-0381-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040678785", 
              "https://doi.org/10.1007/s12272-014-0381-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3239", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047946992", 
              "https://doi.org/10.1038/nrc3239"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri2506", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006865477", 
              "https://doi.org/10.1038/nri2506"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri1349", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039451108", 
              "https://doi.org/10.1038/nri1349"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-015-0055-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009257871", 
              "https://doi.org/10.1186/s40425-015-0055-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-010-0935-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027980911", 
              "https://doi.org/10.1007/s00262-010-0935-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3237", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049465305", 
              "https://doi.org/10.1038/nrc3237"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-014-0040-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022897953", 
              "https://doi.org/10.1186/s40425-014-0040-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2051-1426-2-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032036866", 
              "https://doi.org/10.1186/2051-1426-2-2"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2016-06-21", 
        "datePublishedReg": "2016-06-21", 
        "description": "Key PointsCheckpoint inhibitors have shown promising efficacy and manageable safety profiles for patients with advanced renal cell carcinoma (RCC)The programmed cell death protein 1 (PD-1) inhibitor nivolumab prolongs overall survival in patients with advanced RCC following therapy with an antiangiogenesis agent and has FDA approval in this settingPromising combinations of checkpoint inhibitors with other checkpoint inhibitors or targeted therapies are being compared with antiangiogenic agents for patients with advanced RCC in clinical trialsOther novel immune therapies such as vaccines, cytokine-induced killer cells, and T-cell agonists for advanced RCC are being studied in clinical trialsFurther studies should focus on how to best select patients who will benefit from immune therapies and on how to choose rational combination strategies", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nrurol.2016.103", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2438793", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1034152", 
            "issn": [
              "1759-4812", 
              "1759-4820"
            ], 
            "name": "Nature Reviews Urology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "13"
          }
        ], 
        "keywords": [
          "advanced renal cell carcinoma", 
          "renal cell carcinoma", 
          "checkpoint inhibitors", 
          "advanced RCC", 
          "immune therapy", 
          "cell carcinoma", 
          "cytokine-induced killer cells", 
          "manageable safety profile", 
          "prolongs overall survival", 
          "novel immune therapies", 
          "T cell agonists", 
          "overall survival", 
          "select patients", 
          "novel immunotherapies", 
          "killer cells", 
          "safety profile", 
          "promising efficacy", 
          "antiangiogenic agents", 
          "antiangiogenesis agents", 
          "patients", 
          "FDA approval", 
          "therapy", 
          "carcinoma", 
          "inhibitors", 
          "RCC", 
          "immunotherapy", 
          "vaccine", 
          "agonists", 
          "agents", 
          "efficacy", 
          "survival", 
          "approval", 
          "cells", 
          "study", 
          "profile", 
          "combination"
        ], 
        "name": "Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma", 
        "pagination": "420-431", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1053015375"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nrurol.2016.103"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "27324121"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nrurol.2016.103", 
          "https://app.dimensions.ai/details/publication/pub.1053015375"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:59", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_695.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nrurol.2016.103"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2016.103'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2016.103'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2016.103'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2016.103'


     

    This table displays all metadata directly associated to this object as RDF triples.

    217 TRIPLES      21 PREDICATES      87 URIs      59 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nrurol.2016.103 schema:about N33f8a014aae54b7ea536cb8eb5869ed3
    2 N3a6c25ed14394898bfdcd32a7347eb42
    3 N5c4d82d47716459ea30dcdfc901f72fc
    4 N6ac60046bacd45ab8244ad650d5966e9
    5 Na59e0611a7e349ec8bb13992c59ec341
    6 Nc612201e38cb4941aaf6e8a10c35488d
    7 anzsrc-for:11
    8 anzsrc-for:1107
    9 schema:author N6e96898f520e42b7a488c87d4bb6dad9
    10 schema:citation sg:pub.10.1007/s00262-010-0935-9
    11 sg:pub.10.1007/s12272-014-0381-x
    12 sg:pub.10.1038/bjc.1990.20
    13 sg:pub.10.1038/nature10673
    14 sg:pub.10.1038/nature12213
    15 sg:pub.10.1038/ni.1790
    16 sg:pub.10.1038/nm.2883
    17 sg:pub.10.1038/nrc3237
    18 sg:pub.10.1038/nrc3239
    19 sg:pub.10.1038/nrclinonc.2014.111
    20 sg:pub.10.1038/nrd4591
    21 sg:pub.10.1038/nri1349
    22 sg:pub.10.1038/nri2253
    23 sg:pub.10.1038/nri2506
    24 sg:pub.10.1038/nri3790
    25 sg:pub.10.1186/1471-2407-14-251
    26 sg:pub.10.1186/1479-5876-8-42
    27 sg:pub.10.1186/2051-1426-2-2
    28 sg:pub.10.1186/s40425-014-0040-2
    29 sg:pub.10.1186/s40425-015-0055-3
    30 schema:datePublished 2016-06-21
    31 schema:datePublishedReg 2016-06-21
    32 schema:description Key PointsCheckpoint inhibitors have shown promising efficacy and manageable safety profiles for patients with advanced renal cell carcinoma (RCC)The programmed cell death protein 1 (PD-1) inhibitor nivolumab prolongs overall survival in patients with advanced RCC following therapy with an antiangiogenesis agent and has FDA approval in this settingPromising combinations of checkpoint inhibitors with other checkpoint inhibitors or targeted therapies are being compared with antiangiogenic agents for patients with advanced RCC in clinical trialsOther novel immune therapies such as vaccines, cytokine-induced killer cells, and T-cell agonists for advanced RCC are being studied in clinical trialsFurther studies should focus on how to best select patients who will benefit from immune therapies and on how to choose rational combination strategies
    33 schema:genre article
    34 schema:isAccessibleForFree true
    35 schema:isPartOf N10c347fed50a417aa4b22cfb48d189ec
    36 N9215d7e1a2014652838573b0266244e8
    37 sg:journal.1034152
    38 schema:keywords FDA approval
    39 RCC
    40 T cell agonists
    41 advanced RCC
    42 advanced renal cell carcinoma
    43 agents
    44 agonists
    45 antiangiogenesis agents
    46 antiangiogenic agents
    47 approval
    48 carcinoma
    49 cell carcinoma
    50 cells
    51 checkpoint inhibitors
    52 combination
    53 cytokine-induced killer cells
    54 efficacy
    55 immune therapy
    56 immunotherapy
    57 inhibitors
    58 killer cells
    59 manageable safety profile
    60 novel immune therapies
    61 novel immunotherapies
    62 overall survival
    63 patients
    64 profile
    65 prolongs overall survival
    66 promising efficacy
    67 renal cell carcinoma
    68 safety profile
    69 select patients
    70 study
    71 survival
    72 therapy
    73 vaccine
    74 schema:name Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
    75 schema:pagination 420-431
    76 schema:productId N38343c6b68ca4ee9a782b898e829ae4b
    77 N913cea8b45924ecfa02d916c4dac23cc
    78 Nce501f97bdc8497faf9fd6551f961146
    79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053015375
    80 https://doi.org/10.1038/nrurol.2016.103
    81 schema:sdDatePublished 2022-09-02T15:59
    82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    83 schema:sdPublisher N49c2f0f0ceb54fb98743f0d2a3d522aa
    84 schema:url https://doi.org/10.1038/nrurol.2016.103
    85 sgo:license sg:explorer/license/
    86 sgo:sdDataset articles
    87 rdf:type schema:ScholarlyArticle
    88 N10c347fed50a417aa4b22cfb48d189ec schema:volumeNumber 13
    89 rdf:type schema:PublicationVolume
    90 N33f8a014aae54b7ea536cb8eb5869ed3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    91 schema:name Clinical Trials as Topic
    92 rdf:type schema:DefinedTerm
    93 N38343c6b68ca4ee9a782b898e829ae4b schema:name doi
    94 schema:value 10.1038/nrurol.2016.103
    95 rdf:type schema:PropertyValue
    96 N3a6c25ed14394898bfdcd32a7347eb42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Kidney Neoplasms
    98 rdf:type schema:DefinedTerm
    99 N49c2f0f0ceb54fb98743f0d2a3d522aa schema:name Springer Nature - SN SciGraph project
    100 rdf:type schema:Organization
    101 N5c4d82d47716459ea30dcdfc901f72fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    102 schema:name Humans
    103 rdf:type schema:DefinedTerm
    104 N6ac60046bacd45ab8244ad650d5966e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Carcinoma, Renal Cell
    106 rdf:type schema:DefinedTerm
    107 N6e96898f520e42b7a488c87d4bb6dad9 rdf:first sg:person.013003741441.64
    108 rdf:rest N7b84b4daa4b94541b0dcf45045db92f4
    109 N7b84b4daa4b94541b0dcf45045db92f4 rdf:first sg:person.0577111044.36
    110 rdf:rest Nf0b2ad477f4c4e3e890efe01c139ab0f
    111 N913cea8b45924ecfa02d916c4dac23cc schema:name pubmed_id
    112 schema:value 27324121
    113 rdf:type schema:PropertyValue
    114 N9215d7e1a2014652838573b0266244e8 schema:issueNumber 7
    115 rdf:type schema:PublicationIssue
    116 Na59e0611a7e349ec8bb13992c59ec341 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Immunotherapy
    118 rdf:type schema:DefinedTerm
    119 Nc612201e38cb4941aaf6e8a10c35488d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Cell Cycle Checkpoints
    121 rdf:type schema:DefinedTerm
    122 Nce501f97bdc8497faf9fd6551f961146 schema:name dimensions_id
    123 schema:value pub.1053015375
    124 rdf:type schema:PropertyValue
    125 Nf0b2ad477f4c4e3e890efe01c139ab0f rdf:first sg:person.01234500340.18
    126 rdf:rest rdf:nil
    127 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    128 schema:name Medical and Health Sciences
    129 rdf:type schema:DefinedTerm
    130 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    131 schema:name Immunology
    132 rdf:type schema:DefinedTerm
    133 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1038/nrurol.2016.103
    134 rdf:type schema:MonetaryGrant
    135 sg:journal.1034152 schema:issn 1759-4812
    136 1759-4820
    137 schema:name Nature Reviews Urology
    138 schema:publisher Springer Nature
    139 rdf:type schema:Periodical
    140 sg:person.01234500340.18 schema:affiliation grid-institutes:grid.51462.34
    141 schema:familyName Motzer
    142 schema:givenName Robert J.
    143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
    144 rdf:type schema:Person
    145 sg:person.013003741441.64 schema:affiliation grid-institutes:grid.51462.34
    146 schema:familyName Carlo
    147 schema:givenName Maria I.
    148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013003741441.64
    149 rdf:type schema:Person
    150 sg:person.0577111044.36 schema:affiliation grid-institutes:grid.51462.34
    151 schema:familyName Voss
    152 schema:givenName Martin H.
    153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36
    154 rdf:type schema:Person
    155 sg:pub.10.1007/s00262-010-0935-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027980911
    156 https://doi.org/10.1007/s00262-010-0935-9
    157 rdf:type schema:CreativeWork
    158 sg:pub.10.1007/s12272-014-0381-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040678785
    159 https://doi.org/10.1007/s12272-014-0381-x
    160 rdf:type schema:CreativeWork
    161 sg:pub.10.1038/bjc.1990.20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026132956
    162 https://doi.org/10.1038/bjc.1990.20
    163 rdf:type schema:CreativeWork
    164 sg:pub.10.1038/nature10673 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044278169
    165 https://doi.org/10.1038/nature10673
    166 rdf:type schema:CreativeWork
    167 sg:pub.10.1038/nature12213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021761707
    168 https://doi.org/10.1038/nature12213
    169 rdf:type schema:CreativeWork
    170 sg:pub.10.1038/ni.1790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018507970
    171 https://doi.org/10.1038/ni.1790
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1038/nm.2883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009869790
    174 https://doi.org/10.1038/nm.2883
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1038/nrc3237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049465305
    177 https://doi.org/10.1038/nrc3237
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
    180 https://doi.org/10.1038/nrc3239
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1038/nrclinonc.2014.111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044950640
    183 https://doi.org/10.1038/nrclinonc.2014.111
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1038/nrd4591 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016866071
    186 https://doi.org/10.1038/nrd4591
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1038/nri1349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039451108
    189 https://doi.org/10.1038/nri1349
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1038/nri2253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029881358
    192 https://doi.org/10.1038/nri2253
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1038/nri2506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006865477
    195 https://doi.org/10.1038/nri2506
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1038/nri3790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009414011
    198 https://doi.org/10.1038/nri3790
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1186/1471-2407-14-251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039547181
    201 https://doi.org/10.1186/1471-2407-14-251
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1186/1479-5876-8-42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038769108
    204 https://doi.org/10.1186/1479-5876-8-42
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1186/2051-1426-2-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032036866
    207 https://doi.org/10.1186/2051-1426-2-2
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1186/s40425-014-0040-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022897953
    210 https://doi.org/10.1186/s40425-014-0040-2
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1186/s40425-015-0055-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009257871
    213 https://doi.org/10.1186/s40425-015-0055-3
    214 rdf:type schema:CreativeWork
    215 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA
    216 schema:name Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, New York, USA
    217 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...